A research study of the role of artesunate in the treatment of Fasciola hepatica

A randomised controlled pilot study of artesunate versus triclabendazole for the treatment of human fascioliasis in central Vietnam

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN75869075

Enrollment

100

Registered

2007-03-16

Start date

2005-07-01

Completion date

Unknown

Last updated

2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fasciola hepatica Infections and Infestations Liver fluke infection

Interventions

Group A will be treated using triclabendazole at the recommended dose of 20 mg/Kg body weight and given as two doses of 10 mg/Kg body weight after food with a time lapse of 12 hours between doses. Gr

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Either gender, aged greater than 8 years 2. Fasciola hepatica 3. Gives consent

Exclusion criteria

Exclusion criteria: Does not meet with inclusion criteria

Design outcomes

Primary

Measure	Time frame
Clinical improvement in presenting complaint.	—

Secondary

Measure	Time frame
1. Improvement in ultrasound appearance 2. Changes in eosinophilic count in peripheral blood 3. Biochemical parameters to return to normal 4. Haematology parameters return to normal 5. Absence of eggs in the stool	—

Countries

Viet Nam

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026